18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

Moog, Florian; Bangerter, Markus; Kotzerke, Jbrg; Guhlmann, Albrecht; Frickhofen, Norbert; Reske, Sven N.

doi:10.1200/jco.1998.16.2.603

Cited by 242 publications

(121 citation statements)

References 28 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…18 F-FDG PET/CT has been shown to be sensitive for lymph node staging and for the identification of organ involvement in HD or aggressive NHL. In fact, several studies have been conducted to determine the ability of 18 F-FDG PET or of 18 F-FDG PET/CT to evaluate BM infiltration during the staging of lymphoma [8,9]. Furthermore, the majority of these authors of these studies agree with the idea that 18 F-FDG PET/CT could be useful during evaluations of BM involvement in combination with conventional BMB.…”

Section: Introductionmentioning

confidence: 95%

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Lee

Hwang

Hong

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 95%

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Lee

Hwang

Hong

et al. 2012

Nucl Med Mol Imaging

View full text Add to dashboard Cite

“…F-fluorodeoxyglucose positron emission tomography as a sensitive method for the detection of bone marrow infiltration can provide additional information to that of bone marrow biopsy in the staging of malignant lymphomas (Bangerter et al, 1998;Carr et al, 1998;Moog et al, 1998b;Naumann and Beuthien-Baumann, in press). …”

mentioning

confidence: 99%

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

et al. 2004

Self Cite

View full text Add to dashboard Cite

“…[10][11][12][13][14][15][16] Its increasing availability also has provided an obvious alternative to 67-gallium citrate scans. Many reports have demonstrated the ability of FDG-PET/CT to assess the extension of lymphoma with greater sensitivity than anatomic imaging modalities.…”

mentioning

confidence: 99%

The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation

Filmont¹,

Gisselbrecht²,

Cuenca³

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. In patients with lymphoma who had a poor prognosis, pretransplantation 18‐fluorodeoxyglucose (FDG)‐positron‐emission tomography (PET) was important for the evaluation of response and outcome. However, little is known about the correlation of FDG‐PET with post‐transplantation PET. The current study was designed to ascertain whether positive pretransplantation PET images are modified by the conditioning regimen. METHODS. Sixty consecutive patients who had achieved remission and underwent consolidation by autologous stem cell transplantation (ASCT) had PET images obtained before ASCT (after 3 or 4 chemotherapy cycles) and 100 days after ASCT. The correlation was explored between the presence of abnormal 18‐FDG uptake (PET positive) or its absence (PET negative) and patient outcomes. RESULTS. Before ASCT, 31 patients achieved complete remission (CR), and 23 patients achieved uncertain CR. Before ASCT, 44 patients (75%) were had negative PET images; and, after ASCT, 48 patients (80%) had negative PET images. One year after ASCT, the estimated event‐free survival (EFS) rate was 80% in patients who had negative pre‐ASCT PET images compared with 43% in patients who had positive pre‐ASCT PET images (P = .0002). The EFS rate was 81% in patients who had negative post‐ASCT PET images compared with 25% in patients who had negative post‐ASCT PET images (P < .0001). In multivariate analysis, only the results for pre‐ and post‐ASCT PET images retained prognostic value, with relative risks of failure estimated at 4.9 and 11.9, respectively. CONCLUSIONS. A positive pre‐ASCT PET image indicated a high risk of ASCT failure, which was increased by a positive post‐ASCT PET image. For patients with lymphoma who have positive pre‐ASCT PET images, more investigations using new treatment approaches will be required. For patients who have negative pre‐ASCT PET images, obtaining post‐ASCT PET images does not seem to be mandatory. Cancer 2007. © 2007 American Cancer Society.

show abstract

18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.

Abstract: The results indicate that FDG-PET has a high potential to detect bone marrow involvement in malignant lymphoma. Besides confirming lesions found at BMB, FDG-PET provided additional information, which, in eight of 78 patients (10.3%), led to an upgrade of the tumor stage.

Cited by 242 publications

References 28 publications

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Usefulness of 18F-FDG PET/CT for the Evaluation of Bone Marrow Involvement in Patients with High-Grade Non-Hodgkin’s Lymphoma

Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma

The impact of pre‐ and post‐transplantation positron emission tomography using 18‐fluorodeoxyglucose on poor‐prognosis lymphoma patients undergoing autologous stem cell transplantation

Contact Info

Product

Resources

About